Open forum infectious diseases · 2026
Two Versus One COVID-19 Vaccine Dose After Prior SARS-CoV-2 Infection: A Nationwide Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chemaitelly Hiam, Ayoub Houssein H, Coyle Peter, Tang Patrick, Hasan Mohammad R, Yassine Hadi M, Al Thani Asmaa A, Al-Kanaani Zaina, Al-Kuwari Einas, Jeremijenko Andrew, Kaleeckal Anvar Hassan, Latif Ali Nizar, Shaik Riyazuddin Mohammad, Abdul-Rahim Hanan F, Nasrallah Gheyath K, Al-Kuwari Mohamed Ghaith, Butt Adeel A, Al-Romaihi Hamad Eid, Al-Thani Mohamed H, Al-Khal Abdullatif, Abu-Raddad Laith J
Аннотация
BACKGROUND: Immune protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies by prior infection and vaccination history. This study evaluated whether 2 coronavirus disease (COVID-19) vaccine doses after prior infection provide additional protection compared with a single dose.
METHODS: A national matched retrospective cohort study was conducted in Qatar from December 1, 2020-March 3, 2025. Incidence of SARS-CoV-2 reinfection and severe COVID-19 at reinfection was compared between 61 854 previously infected individuals who completed primary-series vaccination (2-dose cohort) and 61 854 matched individuals who received a single dose (single-dose cohort).
RESULTS: After 360 days of follow-up, cumulative incidence of reinfection was 5.0% (95% CI, 3.8%-6.7%) in the 2-dose cohort and 7.7% (95% CI, 6.1%-9.6%) in the single-dose cohort. No reinfections progressed to severe, critical, or fatal COVID-19 in either cohort. Relative vaccine effectiveness (rVE) of 2 doses vs 1 dose was 38.9% (95% CI, 20.4%-53.2%). The rVE was 26.9% (95% CI, -12.7%-53.4%) within <24 days, 51.8% (95% CI, 19.2%-71.2%) during Days 24-179, and 36.8% (95% CI, 0.9%-59.7%) at ≥180 days of follow-up. Subgroup analyses by time between prior infection and vaccination, prior infection variant, and vaccine type yielded broadly similar rVE estimates, while analyses stratified by age and clinical vulnerability suggested higher point estimates among older and clinically vulnerable individuals.
CONCLUSIONS: Among individuals with prior infection, completion of primary-series vaccination provided modest additional protection against reinfection compared with a single dose. These findings support risk-based dose-optimization strategies in settings with constrained vaccine supply.
METHODS: A national matched retrospective cohort study was conducted in Qatar from December 1, 2020-March 3, 2025. Incidence of SARS-CoV-2 reinfection and severe COVID-19 at reinfection was compared between 61 854 previously infected individuals who completed primary-series vaccination (2-dose cohort) and 61 854 matched individuals who received a single dose (single-dose cohort).
RESULTS: After 360 days of follow-up, cumulative incidence of reinfection was 5.0% (95% CI, 3.8%-6.7%) in the 2-dose cohort and 7.7% (95% CI, 6.1%-9.6%) in the single-dose cohort. No reinfections progressed to severe, critical, or fatal COVID-19 in either cohort. Relative vaccine effectiveness (rVE) of 2 doses vs 1 dose was 38.9% (95% CI, 20.4%-53.2%). The rVE was 26.9% (95% CI, -12.7%-53.4%) within <24 days, 51.8% (95% CI, 19.2%-71.2%) during Days 24-179, and 36.8% (95% CI, 0.9%-59.7%) at ≥180 days of follow-up. Subgroup analyses by time between prior infection and vaccination, prior infection variant, and vaccine type yielded broadly similar rVE estimates, while analyses stratified by age and clinical vulnerability suggested higher point estimates among older and clinically vulnerable individuals.
CONCLUSIONS: Among individuals with prior infection, completion of primary-series vaccination provided modest additional protection against reinfection compared with a single dose. These findings support risk-based dose-optimization strategies in settings with constrained vaccine supply.